NCT05595499View on ClinicalTrials.gov

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Fisetin

Given PO

DRUG

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (7)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

90210

RECRUITING

UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills

90292

RECRUITING

UCLA Health Primary Care in Marina del Rey, Marina del Rey

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

91105

RECRUITING

UCLA Health Primary Care in Pasadena, Pasadena

91505

RECRUITING

UCLA Health Burbank Primary & Specialty Care, Burbank

91801

RECRUITING

UCLA Health Cancer Care in Alhambra, Alhambra

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER